Early response to chemoradiotherapy for nasopharyngeal carcinoma treatment: Value of dynamic contrast-enhanced 3.0 T MRI

Journal of Magnetic Resonance Imaging

Volumn 41, Issue 6, 2015, Pages 1528-1540

  Zheng, Dechun ^a   Chen, Yunbin ^a   Liu, Xiangyi ^a   Chen, Ying ^a   Xu, Luying ^a   Ren, Wang ^a   Chen, Weibo ^b   Chan, Queenie ^b  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b PHILIPS HEALTHCARE   (United States)

Author keywords

DCE MRI; nasopharyngeal carcinoma; neoadjuvant chemotherapy; radiation therapy; therapy response

Indexed keywords

CISPLATIN; GADOLINIUM PENTETATE MEGLUMINE; GEMCITABINE; PACLITAXEL; CONTRAST MEDIUM; GADOLINIUM PENTETATE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; FEMALE; FOLLOW UP; HUMAN; KINETIC PARAMETERS; MALE; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT RESPONSE; NASOPHARYNGEAL NEOPLASMS; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

CHEMORADIOTHERAPY; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84930040253     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.24723     Document Type: Article

References (38)

1. Chang ET, Adami HO,. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 2006; 15: 1765-1777.
2. Sun X, Su S, Chen C, et al., Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. Radiother Oncol 2014; 110: 398-403.
3. Xu T, Zhu G, He X, et al., A phase III randomized study comparing neoadjuvant chemotherapy with concurrent chemotherapy combined with radiotherapy for locoregionally advanced nasopharyngeal carcinoma: updated long-term survival outcomes. Oral Oncol 2014; 50: 71-76.
4. Zhong LP, Zhang CP, Ren GX, et al., Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol 2013; 31: 744-751.
5. Chua DT, Ma J, Sham JS, et al., Improvement of survival after addition of induction chemotherapy to radiotherapy in patients with early-stage nasopharyngeal carcinoma: subgroup analysis of two Phase III trials. Int J Radiat Oncol Biol Phys 2006; 65: 1300-1306.
6. Lin CC, Chen TT, Lin CY, et al., Prognostic analysis of adjuvant chemotherapy in patients with nasopharyngeal carcinoma. Future Oncol 2013; 9: 1469-1476.
7. Lin S, Pan J, Han L, et al., Nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy: report on the 3-year outcome of a prospective series. Int J Radiat Oncol Biol Phys 2009; 75: 1071-1078.
8. Buffa FM, Bentzen SM, Daley FM, et al., Molecular marker profiles predict locoregional control of head and neck squamous cell carcinoma in a randomized trial of continuous hyperfractionated accelerated radiotherapy. Clin Cancer Res 2004; 10: 3745-3754.
9. Powell C, Schmidt M, Borri M, et al., Changes in functional imaging parameters following induction chemotherapy have important implications for individualised patient-based treatment regimens for advanced head and neck cancer. Radiother Oncol 2013; 106: 112-117.
10. Vandecaveye V, Dirix P, De Keyzer F, et al., Predictive value of diffusion-weighted magnetic resonance imaging during chemoradiotherapy for head and neck squamous cell carcinoma. Eur Radiol 2010; 20: 1703-1714.
11. Yopp AC, Schwartz LH, Kemeny N, et al., Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response. Ann Surg Oncol 2011; 18: 2192-2199.
12. Kim JH, Kim CK, Park BK, et al., Dynamic contrast-enhanced 3-T MR imaging in cervical cancer before and after concurrent chemoradiotherapy. Eur Radiol 2012; 22: 2533-2539.
13. Jensen LR, Garzon B, Heldahl MG, et al., Diffusion-weighted and dynamic contrast-enhanced MRI in evaluation of early treatment effects during neoadjuvant chemotherapy in breast cancer patients. J Magn Reson Imaging 2011; 34: 1099-1109.
14. Boehm T, Folkman J, Browder T, et al., Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404-407.
15. Kim S, Loevner LA, Quon H, et al., Prediction of response to chemoradiation therapy in squamous cell carcinomas of the head and neck using dynamic contrast-enhanced MR imaging. AJNR Am J Neuroradiol 2010; 31: 262-268.
16. Hong J, Yao Y, Zhang Y, et al., Value of magnetic resonance diffusion-weighted imaging for the prediction of radiosensitivity in nasopharyngeal carcinoma. Otolaryngol Head Neck Surg 2013; 149: 707-713.
17. Jang HJ, Kim BC, Kim HS, et al., Comparison of RECIST 1.0 and RECIST 1.1 on computed tomography in patients with metastatic colorectal cancer. Oncology 2014; 86: 117-121.
18. Wang HZ, Riederer SJ, Lee JN,. Optimizing the precision in T1 relaxation estimation using limited flip angles. Magn Reson Med 1987; 5: 399-416.
19. Daldrup H, Shames DM, Wendland M, et al., Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: correlation of macromolecular and small-molecular contrast media. AJR Am J Roentgenol 1998; 171: 941-949.
20. Hittmair K, Gomiscek G, Langenberger K, et al., Method for the quantitative assessment of contrast agent uptake in dynamic contrast-enhanced MRI. Magn Reson Med 1994; 31: 567-571.
21. Tofts PS, Brix G, Buckley DL, et al., Estimating kinetic parameters from dynamic contrast enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999; 10: 223-232.
22. Murase K,. Efficient method for calculating kinetic parameters using T1-weighted dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Med 2004; 51: 858-862.
23. Benjaminsen IC, Graff BA, Brurberg KG, et al., Assessment of tumor blood perfusion by high-resolution dynamic contrast-enhanced MRI: a preclinical study of human melanoma xenografts. Magn Reson Med 2004; 52: 269-276.
24. Zheng D, Chen Y, Chen Y, et al., Dynamic contrast-enhanced MRI of nasopharyngeal carcinoma: a preliminary study of the correlations between quantitative parameters and clinical stage. J Magn Reson Imaging 2014; 39: 940-948.
25. Zheng D, Chen Y, Chen Y, et al., Early assessment of induction chemotherapy response of nasopharyngeal carcinoma by pretreatment diffusion-weighted magnetic resonance imaging. J Comput Assist Tomogr 2013; 37: 673-680.
26. Hardt N, van Nagell JR, Hanson M, et al., Radiation-induced tumor regression as a prognostic factor in patients with invasive cervical cancer. Cancer 1982; 49: 35-39.
27. Hong JH, Chen MS, Lin FJ, et al., Prognostic assessment of tumor regression after external irradiation for cervical cancer. Int J Radiat Oncol Biol Phys 1992; 22: 913-917.
28. Türkbey B, Thomasson D, Pang Y, et al., The role of dynamic contrast-enhanced MRI in cancer diagnosis and treatment. Diagn Interv Radiol 2010; 16: 186-192.
29. Halle C, Andersen E, Lando M, et al., Hypoxia-induced gene expression in chemoradioresistant cervical cancer revealed by dynamic contrast-enhanced MRI. Cancer Res 2012; 72: 5285-5289.
30. Jansen JF, Schöder H, Lee NY, et al., Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET. Int J Radiat Oncol Biol Phys 2012; 82: 299-307.
31. Ellingsen C, Egeland TA, Gulliksrud K, et al., Assessment of hypoxia in human cervical carcinoma xenografts by dynamic contrast-enhanced magnetic resonance imaging. Int J Radiat Oncol Biol Phys 2009; 73: 838-845.
32. Kim H, Folks KD, Guo L, et al., Early therapy evaluation of combined cetuximab and irinotecan in orthotopic pancreatic tumor xenografts by dynamic contrast-enhanced magnetic resonance imaging. Mol Imaging 2011; 10: 153-167.
33. Gulliksrud K, Øvrebø KM, Mathiesen B, et al., Differentiation between hypoxic and non-hypoxic experimental tumors by dynamic contrast-enhanced magnetic resonance imaging. Radiother Oncol 2011; 98: 360-364.
34. Chikui T, Kitamoto E, Kawano S, et al., Pharmacokinetic analysis based on dynamic contrast-enhanced MRI for evaluating tumor response to preoperative therapy for oral cancer. J Magn Reson Imaging 2012; 36: 589-597.
35. Yoo DS, Kirkpatrick JP, Craciunescu O, et al., Prospective trial of synchronous bevacizumab, erlotinib, and concurrent chemoradiation in locally advanced head and neck cancer. Clin Cancer Res 2012; 18: 1404-1414.
36. Gu J, Khong PL, Wang S, et al., Combined use of 18F-FDG PET/CT, DW-MRI, and DCE-MRI in treatment response for preoperative chemoradiation therapy in locally invasive rectal cancers. Clin Nucl Med 2013; 38: e226-229.
37. Skinner JT, Yankeelov TE, Peterson TE, et al., Comparison of dynamic contrast-enhanced MRI and quantitative SPECT in a rat glioma model. Contrast Media Mol Imaging 2012; 7: 494-500.
38. Tofts P,. Modelling in DCE MRI. http://www.paul-tofts-phd.org.uk/talks/esmi2012-talk.pdf.